Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ocular Therapeutix, with a price target of $27....

Bank of America Securities Sticks to Its Buy Rating for Ocular Therapeutix (OCUL)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (O...

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocular Therapeutix (OCUL) and Addus Homecare (ADUS) ...

Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL) and Addus Homecare (ADUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocular Therapeutix (OCUL) and Twist Bioscience (TWST...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCUL	$9.19	+5.15%	2.02M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OCUL	$9.19	+5.1%	2.02M
3
4
5
6

OCUL

OCUL

Get Ocular Therapeutix, Inc. Data in Excel

Get Ocular Therapeutix, Inc. Data in Excel